A bold initiative to disrupt the landscape of cancer treatment in India, Immuneel is a privately-owned Indian clinical stage startup company established in 2018, and seed-funded through angel investments and institutional capital.
A first mover in India, Immuneel is pioneering the business and care delivery models which will transform the way cell and gene therapies are developed and manufactured while alleviating the suffering of an under-served population.
With an inspired leadership team and a wide sweep of capabilities being built, Immuneel has garnered support from leading investors across hospitals, corporates and institutions on its journey towards scale, reliability and speed.
Please contact investors@localhost/immuneel for any queries related to investor relations.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
This website uses the following additional cookies:
(List the cookies that you are using on the website here.)
Please enable Strictly Necessary Cookies first so that we can save your preferences!
More information about our Cookie Policy